Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lesion Dosimetry for [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer.
Grkovski M, O'Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, Schwartz J, Thor M, Zelefsky MJ, Humm JL, Bodei L. Grkovski M, et al. Among authors: bodei l. J Nucl Med. 2023 Nov;64(11):1779-1787. doi: 10.2967/jnumed.123.265763. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652541 Free PMC article.
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. Among authors: bodei l. medRxiv [Preprint]. 2024 Jan 11:2024.01.10.24301109. doi: 10.1101/2024.01.10.24301109. medRxiv. 2024. PMID: 38260492 Free PMC article. Preprint.
Neuroendocrine Tumor Therapy Response Assessment.
Jayaprakasam VS, Bodei L. Jayaprakasam VS, et al. Among authors: bodei l. PET Clin. 2023 Apr;18(2):267-286. doi: 10.1016/j.cpet.2022.11.009. PET Clin. 2023. PMID: 36858748 Review.
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.
Bodei L, Michael Tuttle R, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne JR, Haque S, Wong BZY, Ghossein RA, Fagin J, Schӧder H, Ho A, Humm JL, Larson SM. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):325-329. doi: 10.1007/s00259-023-06420-z. Eur J Nucl Med Mol Imaging. 2024. PMID: 37712994 Free PMC article. No abstract available.
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL; NET CTPM participants. Singh S, et al. Among authors: bodei l. J Natl Cancer Inst. 2023 Sep 7;115(9):1001-1010. doi: 10.1093/jnci/djad096. J Natl Cancer Inst. 2023. PMID: 37255328
211 results